BRIC IVD Market Future Insights and Demand across Major Geographies
The BRIC IVD Market and other emerging countries is expected to reach USD 15.71 Billion by 2022 from USD 10.60 Billion in 2017, at a CAGR of 8.2%.
The BRIC IVD Market and other emerging countries is expected to reach USD 15.71 Billion by 2022 from USD 10.60 Billion in 2017, at a CAGR of 8.2%.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>BRIC</strong> <strong>IVD</strong> <strong>Market</strong>: <strong>Future</strong> <strong>Insights</strong> <strong>and</strong> Dem<strong>and</strong> <strong>across</strong><br />
<strong>Major</strong> <strong>Geographies</strong><br />
The rising incidence of chronic diseases, growth in the number of private diagnostic centers, <strong>and</strong><br />
rising consolidation of laboratories are the key factors driving the market growth. However,<br />
inadequate reimbursement <strong>and</strong> the slow growth of the economy are the factors restraining the<br />
growth of this market.<br />
Download FREE Brochure<br />
@https://www.markets<strong>and</strong>markets.com/pdfdownloadNew.asp?id=198<br />
How <strong>Market</strong> is Growing?<br />
The <strong>BRIC</strong> <strong>IVD</strong> <strong>Market</strong> <strong>and</strong> other emerging countries is expected to reach USD 15.71 Billion by<br />
2022 from USD 10.60 Billion in 2017, at a CAGR of 8.2%.<br />
Based on product & service, the market is segmented into reagents & kits, instruments, services,<br />
<strong>and</strong> data management software. The reagents & kits segment accounted for the largest share of<br />
the market in 2016.<br />
On the basis of application, the market is segmented into diabetes, infectious diseases,<br />
oncology/cancer, cardiology, HIV/AIDS, autoimmune diseases, nephrology, drug<br />
testing/pharmacogenomics, <strong>and</strong> other applications.<br />
In 2016, China accounted for the largest share in the market, followed by Brazil. Rising<br />
government initiatives <strong>and</strong> improving healthcare infrastructure, <strong>and</strong> increasing geriatric<br />
population are driving the market growth in China. Brazil accounted for second-largest share in<br />
the <strong>BRIC</strong> <strong>IVD</strong> <strong>Market</strong> <strong>and</strong> other emerging countries
Top Key Players<br />
The <strong>BRIC</strong> <strong>IVD</strong> <strong>Market</strong> <strong>and</strong> other emerging countries is highly competitive in nature, with the top<br />
five companies accounting for the major market share in 2016. Some key players in this market<br />
are Roche Diagnostics (Switzerl<strong>and</strong>), Abbott Laboratories Inc. (U.S.), Siemens Healthineers<br />
(Germany), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sysmex Corporation<br />
(Japan), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Becton, Dickinson <strong>and</strong> Company<br />
(U.S.), Johnson & Johnson (U.S.), QIAGEN N.V. (Germany), Ortho-Clinical Diagnostics, Inc. (U.S.),<br />
<strong>and</strong> Diasorin S.P.A. (Italy).<br />
These leading players have primarily focused on product launches, acquisitions, agreements,<br />
collaboration, partnerships, <strong>and</strong> expansions for growth in the market.<br />
Request for Sample @https://www.markets<strong>and</strong>markets.com/requestsampleNew.asp?id=198<br />
Target Audience<br />
• <strong>IVD</strong> product manufacturers<br />
• Group purchase organizations (GPOs)<br />
• Original equipment manufacturers (OEM)<br />
• Pathologists <strong>and</strong> pathology laboratories<br />
• Distributors of <strong>IVD</strong> products<br />
• Hospitals <strong>and</strong> clinics
• Healthcare institutions
Change language